Nasopharynx Cancer
10
3
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
80.0%
-6.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (10)
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
U87 CAR-T in Patients With Advanced Head and Neck Tumors
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma
Adaptive Radiotherapy for Head and Neck Cancer
Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx